Quick Answer
Monopar Therapeutics reported Stockholders Equity of $137.83 million for the year ending 2025.
- Monopar Therapeutics showed an increase of +150.4% in Stockholders Equity from 2024 to 2025.
- This data is from Monopar Therapeutics's annual report (Form 10-K), filed with the SEC on March 27, 2026.
- XBRL data for this metric is available from 2015 to 2025 (11 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q4 2017: $9.62 million | Q1 2018: $8.86 million | Q2 2018: $8.12 million | Q3 2018: $7.58 million | Q1 2019: $5.77 million | Q2 2019: $5.13 million | Q3 2019: $4.62 million | Q1 2020: $12.40 million | Q2 2020: $12.15 million | Q3 2020: $17.49 million | Q1 2021: $25.10 million | Q2 2021: $23.35 million | Q3 2021: $21.28 million | Q1 2022: $16.97 million | Q2 2022: $14.52 million | Q3 2022: $12.51 million | Q1 2023: $8.94 million | Q2 2023: $7.84 million | Q3 2023: $6.61 million | Q1 2024: $7.48 million | Q2 2024: $6.09 million | Q3 2024: $4.95 million | Q1 2025: $53.59 million | Q2 2025: $52.20 million | Q3 2025: $141.56 million.
- Over the full 11 years of available data (2015 to 2025), Monopar Therapeutics's Stockholders Equity has grown by 4,904.4%.
- Historical annual values: Fiscal year 2025: $137.83 million | Fiscal year 2024: $55.04 million | Fiscal year 2023: $5.59 million | Fiscal year 2022: $10.09 million | Fiscal year 2021: $18.94 million | Fiscal year 2020: $15.69 million | Fiscal year 2019: $12.63 million | Fiscal year 2018: $6.92 million | Fiscal year 2017: $9.62 million | Fiscal year 2016: $2.83 million | Fiscal year 2015: $2.75 million.
- Data sourced from SEC EDGAR public filings as of August 4, 2026.
Last verified: